Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| RSF-MY2092 | Mouse | Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (5A3) (MALS verified) |
|
|
|
| RSF-MY2093 | Mouse | Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (MALS verified) |
|
|
Immobilized Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (Cat. No. RSF-MY2093) with a linear range of 0.06-2 ng/mL (QC tested).
The purity of Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (5A3) (Cat. No. RSF-MY2092) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus immune globulin | RSV-IGIV | Approved | Medimmune | RespiGam | Canada | Respiratory Syncytial Virus Infections | Medimmune Llc | 1996-01-01 | Respiratory Syncytial Virus Infections | Details |
| Nirsevimab | Anti-RSV MAb-YTE; Anti-RSV-mAb-D25; SP-0232; MEDI-8897 | Approved | Aimm Therapeutics, Sanofi, MedImmune Inc | Beyfortus | EU | Respiratory Syncytial Virus Infections | Astrazeneca Ab | 2022-10-31 | Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections | Details |
| Palivizumab | ABT-315; MEDI-493 | Approved | Abbvie Inc, Medimmune Llc | Synagis | Japan | Respiratory Syncytial Virus Infections | Abbvie Inc | 1998-06-19 | Bronchopulmonary Dysplasia; Respiratory Syncytial Virus Infections; Heart Defects, Congenital; Premature Birth; Infant, Premature, Diseases | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Motavizumab biosimilar (MedImmune) | MEDI-557 | Medimmune Llc | Details | ||
| Motavizumab | MEDI-524 | Medimmune Llc | Details | ||
| CPI-RSV-F Vaccine | BLB-201 | Phase 1 Clinical | Blue Lake Biotechnology Inc | Respiratory Syncytial Virus Infections | Details |
| Ziresovir | RO-0529; AK-0529 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Respiratory Syncytial Virus Infections | Details |
This web search service is supported by Google Inc.
A-Z
